Sumitomo Pharma Co., Ltd. (TYO:4506)
1,565.00
-55.00 (-3.40%)
May 19, 2026, 2:05 PM JST
Sumitomo Pharma Revenue
In the fiscal year ending March 31, 2026, Sumitomo Pharma had annual revenue of 453.29B JPY with 13.66% growth. Sumitomo Pharma had revenue of 105.55B in the quarter ending March 31, 2026, a decrease of -0.10%.
Revenue
453.29B
Revenue Growth
+13.66%
P/S Ratio
1.60
Revenue / Employee
118.29M
Employees
3,832
Market Cap
726.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 453.29B | 54.46B | 13.66% |
| Mar 31, 2025 | 398.83B | 84.27B | 26.79% |
| Mar 31, 2024 | 314.56B | -240.99B | -43.38% |
| Mar 31, 2023 | 555.54B | -4.49B | -0.80% |
| Mar 31, 2022 | 560.04B | 44.08B | 8.54% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Toho Holdings | 1.55T |
| Eisai | 808.19B |
| Shionogi & | 499.68B |
| Towa Pharmaceutical | 269.92B |
| Sawai Group Holdings | 200.68B |
| Tsumura & Co. | 192.62B |
| Nippon Shinyaku | 166.05B |
| Mochida Pharmaceutical | 111.92B |
Sumitomo Pharma News
- 16 hours ago - New Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPH - Business Wire
- 3 months ago - Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment - CNBC
- 9 months ago - Sumitomo Pharma upgraded to Equal Weight from Underweight at Morgan Stanley - TheFly
- 1 year ago - Sumitomo Pharma upgraded to Neutral from Sell at Citi - TheFly
- 1 year ago - Sumitomo Pharma, Poxel announce topline results from TWINKLE study - TheFly
- 3 years ago - Sumitomo Pharma upgraded to Buy from Hold at Jefferies - TheFly
- 3 years ago - Sumitomo Pharma granted orphan status for Ewing sarcoma treatment - TheFly